SCHEDULE: ARCH Venture Funds Hold 13% Stake in Lyell Immunopharma

ARCH Venture Funds and associated individuals collectively report a 13.0% beneficial ownership in Lyell Immunopharma, Inc. common stock.

Summary

• ARCH Venture Fund IX, L.P., ARCH Venture Fund IX Overage, L.P., ARCH Venture Fund XIII, L.P., and their general partners, along with several managing directors and investment committee members (Keith Crandell, Robert Nelsen, Kristina Burow, Steven Gillis), collectively beneficially own 2,759,072 shares of Lyell Immunopharma, Inc. common stock.
• This represents 13.0% of the total class of securities outstanding.
• Clinton Bybee beneficially owns 1,820,634 shares, representing 8.6% of the class.
• Paul Berns beneficially owns 938,438 shares, representing 4.4% of the class.
• The percentages are based on 21,218,217 shares of common stock outstanding as of November 10, 2025, as reported in Lyell Immunopharma's Form 10-Q filed on November 12, 2025.
• The filing is an Amendment No. 3 to a Schedule 13G.

Sentiment

Score: 7

Explanation: The filing indicates a substantial and continued beneficial ownership by ARCH Venture Partners, a reputable venture capital firm, in Lyell Immunopharma. This suggests ongoing institutional confidence in the company, which is generally viewed positively by the market.

Positives

• Significant beneficial ownership by a prominent venture capital firm (ARCH Venture Partners) indicates continued institutional confidence in Lyell Immunopharma.
• Multiple key individuals associated with ARCH Venture Partners also hold substantial shared beneficial ownership, aligning their interests with the company's performance.

Future Outlook

NA

Industry Context

This filing reflects the continued investment by a prominent venture capital firm, ARCH Venture Partners, in the biotechnology sector, specifically in Lyell Immunopharma, Inc., which operates in the cell therapy and immunotherapy space. Such significant institutional holdings are common in early to mid-stage biotech companies, where venture capital plays a crucial role in funding research and development.

Comparison to Industry Standards

• ARCH Venture Partners is a well-known venture capital firm with a strong track record in life sciences, often taking significant stakes in promising biotechnology companies.
• A 13.0% stake by a single institutional group is a substantial position, indicating a high level of conviction, which is typical for lead investors in biotech startups or early-stage public companies.
• The beneficial ownership structure, involving multiple funds and individual managing directors, is standard for venture capital investments, reflecting the complex ownership and governance structures common in the industry.

Stakeholder Impact

• Shareholders: The significant institutional ownership by ARCH Venture Partners may instill confidence among other shareholders, signaling a strong belief in the company's long-term prospects.
• Management: The presence of a major institutional investor like ARCH Venture Partners can provide strategic guidance and oversight, potentially influencing management decisions.

Key Dates

Recommendation

This Schedule 13G filing primarily discloses beneficial ownership by ARCH Venture Partners and associated individuals in Lyell Immunopharma. While the substantial institutional stake (13.0%) by a reputable venture capital firm is a positive signal of confidence, the filing itself does not contain operational or financial performance data to warrant a 'buy' or 'sell' recommendation. It confirms a significant existing investment, suggesting a 'hold' position for investors awaiting further fundamental updates on the company's progress.

Keywords

Lyell Immunopharma, ARCH Venture Partners, Beneficial Ownership, Schedule 13G, Common Stock, Institutional Investor, Biotechnology, Venture Capital